Oragenics (OGEN, Financial) has disclosed that its Board of Directors has sanctioned a one-for-thirty reverse stock split of the company's common shares, each with a par value of $0.001. This decision was reached on May 27, 2025. Investors can expect the company's stock to commence trading on a split-adjusted basis starting June 3, 2025, when the markets open.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Oragenics Inc (OGEN, Financial) is $1.00 with a high estimate of $1.00 and a low estimate of $1.00. The average target implies an upside of 420.83% from the current price of $0.19. More detailed estimate data can be found on the Oragenics Inc (OGEN) Forecast page.
Based on the consensus recommendation from 1 brokerage firms, Oragenics Inc's (OGEN, Financial) average brokerage recommendation is currently 3.0, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
